Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$6.85 +1.0%	$5.23	$2.32 ▼ $10.13	$369.76M	2.41	963,095 shs	247,184 shs
ITOS iTeos Therapeutics	$10.17 +1.9%	$7.84	$4.80 ▼ $18.13	$389.25M	1.51	672,067 shs	1.11 million shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.30 ▼ $6.65	$381.02M	0.9	3.48 million shs	N/A
SNTI Senti Biosciences	$2.60 -9.1%	$3.37	$1.52 ▼ $16.94	$67.81M	2.23	805,885 shs	94,636 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	+1.03%	-5.52%	+21.67%	+119.55%	-11.15%
ITOS iTeos Therapeutics	+1.90%	0.00%	+33.82%	+38.93%	-38.25%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	+20.66%
SNTI Senti Biosciences	-9.09%	-32.29%	-19.00%	-25.50%	-3.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FULC Fulcrum Therapeutics	0.4285 of 5 stars	1.3	0.0	0.0	2.8	2.5	0.0
ITOS iTeos Therapeutics	3.7127 of 5 stars	4.1	4.0	0.0	2.3	3.3	0.6
RVNC Revance Therapeutics	2.5685 of 5 stars	3.1	0.0	4.7	0.0	1.7	0.6
SNTI Senti Biosciences	2.3354 of 5 stars	3.5	3.0	0.0	1.9	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-8.24% Downside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	55.92% Upside
RVNC Revance Therapeutics	2.13	Hold	$8.45	131.51% Upside
SNTI Senti Biosciences	3.00	Buy	$8.50	226.92% Upside

Current Analyst Ratings Breakdown

Latest SNTI, FULC, ITOS, and RVNC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/6/2025	SNTI Senti Biosciences	Laidlaw Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	4.62	N/A	N/A	$3.80 per share	1.80
ITOS iTeos Therapeutics	$35M	11.12	N/A	N/A	$16.08 per share	0.63
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
SNTI Senti Biosciences	$2.56M	26.49	N/A	N/A	$15.02 per share	0.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	7/30/2025 (Estimated)
ITOS iTeos Therapeutics	-$112.64M	-$3.04	N/A	N/A	N/A	N/A	-20.11%	-17.50%	8/6/2025 (Estimated)
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	8/6/2025 (Estimated)
SNTI Senti Biosciences	-$71.06M	-$10.84	N/A	N/A	N/A	N/A	-154.84%	-77.42%	8/12/2025 (Estimated)

Latest SNTI, FULC, ITOS, and RVNC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	SNTI Senti Biosciences	-$0.56	-$1.41	-$0.85	-$1.41	$1.30 million	$1.30 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
3/20/2025	Q4 2024	SNTI Senti Biosciences	-$3.13	-$0.67	+$2.46	-$0.67	$2.80 million	$5.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	18.44	18.44
ITOS iTeos Therapeutics	N/A	14.80	14.80
RVNC Revance Therapeutics	N/A	4.12	3.05
SNTI Senti Biosciences	N/A	1.92	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
ITOS iTeos Therapeutics	97.16%
RVNC Revance Therapeutics	97.70%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.00%
ITOS iTeos Therapeutics	12.50%
RVNC Revance Therapeutics	5.10%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	31.97 million	Optionable
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
SNTI Senti Biosciences	4	26.08 million	4.30 million	Not Optionable

SNTI, FULC, ITOS, and RVNC Headlines

Recent News About These Companies

Chardan Capital Reaffirms Buy Rating for Senti Biosciences (NASDAQ:SNTI)

June 14 at 1:31 AM | americanbankingnews.com

Chardan Capital Reaffirms "Buy" Rating for Senti Biosciences (NASDAQ:SNTI)

June 12 at 8:22 AM | marketbeat.com

Senti Biosciences Announces New Employment Inducement Grants

June 9, 2025 | globenewswire.com

Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI)

June 8, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 7, 2025 | prnewswire.com

Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation

June 7, 2025 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 6, 2025 | globenewswire.com

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

June 6, 2025 | globenewswire.com

Senti Biosciences (NASDAQ:SNTI) Coverage Initiated at Laidlaw

June 6, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 5, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 4, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 3, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 2, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 1, 2025 | prnewswire.com

Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

June 1, 2025 | marketbeat.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc

May 30, 2025 | accessnewswire.com

Senti Biosciences (NASDAQ:SNTI) Stock Price Down 3% - Time to Sell?

May 30, 2025 | marketbeat.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc

May 29, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 29, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Into Senti Biosciences Inc

May 28, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 28, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, FULC, ITOS, and RVNC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$6.85 +0.07 (+1.03%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$6.82 -0.03 (-0.50%)

As of 06/13/2025 04:47 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

iTeos Therapeutics NASDAQ:ITOS

$10.17 +0.19 (+1.90%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.17 0.00 (0.00%)

As of 06/13/2025 04:44 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Revance Therapeutics NASDAQ:RVNC

$3.65 0.00 (0.00%)

As of 02/6/2025

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Senti Biosciences NASDAQ:SNTI

$2.60 -0.26 (-9.09%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.67 +0.07 (+2.69%)

As of 06/13/2025 07:47 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time